Public Event Detail
aTYR Pharma director Paul Schimmel buys $49,630 in common stock
Public historical observation from the Merrowstone archive. This page shows event-level context only. Accepted assertions, evidence lineage, and relationship intelligence remain part of the premium research layer.
Historical observations only. No forecasts, recommendations, buy/sell ratings, or portfolio advice.
2026-05-28AAPLAppleAlpha Vantage Newsalpha_vantage_news
Event summary
aTYR Pharma Inc. director Paul Schimmel recently purchased 100,000 shares of the company's common stock for $49,630, with the stock trading near its 52-week low. This insider buy increases his indirect holdings to over 779,000 shares through a trust and over 1.4 million shares directly. The purchase comes as investment analysis suggests ATYR is undervalued, with a fair value of $0.61, and the company prepares for a new Phase 3 study for its drug efzofitimod.
Attached public signals
Observed outcomes
7d returnPending
30d returnPending
90d returnPending
Relative 90d returnPending